Terms ending in 2039
Every in-force patent on BioAtla Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,834,472 | Anti-Il-22 Antibodies, Antibody Fragments,Their Immunoconjugates And Uses Thereof In force · High confidence | BioAtla, Inc. | In force | High confidence | |
| US 11,542,332 | ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof In force · High confidence | BioAtla, Inc. | In force | High confidence | |
| US 12,649,793 | ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof In force · Low confidence | BioAtla, Inc. | In force | Low confidence | |
| US 11,413,340 | Mesothelin Chimeric Antigen Receptor (CAR) and Antibody Against PD-L1 Inhibitor for Combined Use in Anticancer Therapy In force · High confidence | President and Fellows of Harvard College | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by BioAtla Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.